In a research note issued Thursday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Atossa (ATOS), with a $10 price target, …
Atossa Genetics Inc (NASDAQ:ATOS) investors are upbeat today upon news that this biotech player’s breast health program is getting an expansion. Specifically, the …
Following Phase 1 trial data for Atossa’s oral endoxifen, Maxim’s Jason Kolbert spotlights 208% in return potential for the stock.
Atossa Genetics is among the biotech stock movers in after-hours trading Thursday.
Maxim’s Jason Kolbert sheds light ahead of tomorrow’s Phase 1 oral endoxifen findings.
Analyst sees a bright future on the horizon.
Atossa Genetics may have taken a beating in the market yesterday after investors ran for the hills with fears of share dilution running …
